Navigation Links
GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
Date:1/30/2009

lated to infusion reactions and infections. AEs seen in at least 10 percent of patients included fever, cough, diarrhea, rash, low white blood cell counts, fatigue, pneumonia, anemia, shortness of breath and nausea. In clinical trials to date, infusion reactions that were serious yet manageable were seen in three percent of patients. One case of progressive multifocal leukoencephalopathy (PML), a rare brain infection resulting in death or causing severe disability, and one case of tumor lysis syndrome were reported.(5,6) These data were presented at the 50th Annual Meeting of the American Society of Hematology (ASH) in December 2008.

Potential to Combat CLL in Earlier Stages

The companies also announced today the initiation of an additional Phase III study of ofatumumab in combination with fludarabine and cyclophosphamide (FC) for patients with CLL when initial treatment no longer works (second-line treatment). The open-label study will randomize 352 patients to evaluate progression-free survival (PFS) of ofatumumab in combination with FC therapy versus FC therapy alone for the treatment of relapsed CLL.(7) Enrollment for this study will begin shortly.

"Bolstered by the positive results of ofatumumab for advanced stage CLL, we're now investigating ofatumumab in earlier stages in the treatment continuum," said Paolo Paoletti, M.D., Senior Vice President of Oncology R&D, GSK. "The clues we're seeing from ofatumumab also suggest possible activity in other oncology settings, which we're currently evaluating through several clinical trials."

GSK and Genmab will conduct additional studies of ofatumumab in CLL and non-Hodgkin's lymphoma (NHL) settings. In CLL, a Phase III front-line study is evaluating ofatumumab combined with chlorambucil in patients with previously untreated CLL. In NHL, an ongoing Phase II study will assess ofatumumab in patients with Waldenstrom's Macroglobulinemia - a rare type of
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. GlaxoSmithKlines Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL
2. GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding
3. GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance : – Developing First-in-Class Endosomal TLR Inhibitors for Autoimmune and Inflammatory Diseases –
4. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
5. GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program
6. GlaxoSmithKline to Acquire the Leading Dry Mouth Brand, Biotene
7. AUDIO from Medialink and GlaxoSmithKline: Give Kids A Boost For Their Health!
8. GlaxoSmithKline Acquires Sirtris Pharmaceuticals, Inc., a World Leader in Sirtuin Research and Development
9. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
10. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
11. Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 2015 According to a recent report ... after chronic back pain, TMJ disorders are the ... and disability. In addition, the report revealed that TMJ ... population, costing an estimated 4 billion dollars annually. , ... from seemingly unrelated symptoms such as headaches, neck pain, ...
(Date:4/27/2015)... 2015 The Doctors on Liens ... of personal injury attorneys with the best doctors working on ... steady growth throughout their history and that trend continues with ... and his team in the Tujunga / Sunland ... massage therapist, patients can find comprehensive care and detailed documentation ...
(Date:4/27/2015)... NJ (PRWEB) April 27, 2015 ... firm, is proud to announce their sponsorship of ... Warren Counties. Girls on the Run is ... third through eighth grade. The program is delivered ... with uplifting workouts aimed to develop the whole ...
(Date:4/27/2015)... April 27, 2015 Ticket Down is ... at the Alpine Valley Music Theatre and the Isleta ... and Albuquerque, New Mexico area can celebrate because their ... the woods. Buffett will be performing alongside legendary ... His tour stops during the summer and fall months ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 The Mount ... a seamless referral process for the Health System’s care ... heart failure or diabetes, for instance, may have more ... physicians coordinate with many other care providers. With medical ... of thousands of patients each year, the need for ...
Breaking Medicine News(10 mins):Health News:Dentist in Graham NC Reveals that a Jaw Disorder May Be the Cause of Chronic Headaches and Back Pain 2Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:TayganPoint Consulting Group Announces Sponsorship of Girls on the Run 2Health News:Cheap Jimmy Buffett Tickets at Alpine Valley Music Theatre in Elkhorn, WI and at Isleta Amphitheater in Albuquerque, NM Now on Sale at TicketDown.com 2Health News:Mount Sinai Launches System for Faster Referrals 2Health News:Mount Sinai Launches System for Faster Referrals 3
... ... contacted the Metropolitan Washington, DC Chapter of the Cystic Fibrosis (CF) Foundation 12 ... Melissa and 3-year old son Matthew had recently been diagnosed with the genetic ... age of survival for a child with CF was about 20 years. ...
... ... falling apart at home, psychotherapeutic interventions provide families with a growing array of options. ... (PRWEB) February 25, 2010 -- ... apart at home, psychotherapeutic interventions provide families with a growing array of options., , ,There ...
... ... braking system, affects millions of drivers , ... New York, NY (Lexis Nexis) February 25, 2010 -- The ... led to a significant increase in inquiries from individuals who are concerned about the ...
... A new study found that fluoxetine (Prozac) and ... collagen-induced arthritis (CIA) in mice. Research led ... Sussex Medical School (BSMS) in the UK studied ... selective serotonin reuptake inhibitors (SSRIs), most commonly used ...
... Special Issue of Business Horizons ( www.elsevier.com/locate/bushor ... Indiana University, and published by Elsevier, addresses issues central ... has been at the center of U.S. political debate ... support from Congress for passage of a national system ...
... ... ... ... ...
Cached Medicine News:Health News:Cystic Fibrosis Foundation Awards CGI Corporation of the Year 2Health News:Cystic Fibrosis Foundation Awards CGI Corporation of the Year 3Health News:New Approaches to Teen Therapy Bring Results 2Health News:New Approaches to Teen Therapy Bring Results 3Health News:New Approaches to Teen Therapy Bring Results 4Health News:New Approaches to Teen Therapy Bring Results 5Health News:Toyota Recalls Raise Awareness of Vehicle Safety Issues, Risks of Accidents from Driving Defective Automobiles 2Health News:Prozac and Celexa exhibit anti-inflammatory effects 2Health News:New Business Horizons special issue on US health care 2Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 2Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 3Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 4Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 5Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 6Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 7
(Date:4/27/2015)... , April 27, 2015   AMC Health , ... showcase advances in monitored care that are transforming chronic ... ATA 2015 Conference, May 2-5 at the ... Health will share information about how their innovative ... help transform and personalize healthcare delivery at Booth #2116 ...
(Date:4/27/2015)... NEW YORK , April 27, 2015 ... claims against the board of directors of Aerie Pharmaceuticals, ... concerning whether the board has breached its fiduciary duties ... Company issued a press release announcing results from its ... things, the press release disclosed that in the trial, ...
(Date:4/27/2015)... 2015  USL di Reggio Emilia, the Regional Health ... has implemented Zebra Technologies Corporation (NASDAQ: ... Wireless Network Solution (WNS) provided by Zebra has ... in real time via mobile computers, contributing to improved ... also provides employee and guest Wi-Fi access and enables ...
Breaking Medicine Technology:AMC Health to Showcase Advances in Monitored Care at ATA 2015 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 3AMC Health to Showcase Advances in Monitored Care at ATA 2015 4Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 2Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 3Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 4Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 5
... NEW YORK, Nov. 9 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. ... pharmaceutical,company dedicated to improving health through the development, manufacture ... the counter ("OTC"),products, today announced that it plans to ... 2009, after the market closes. , ...
... 9, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) today ... , Arena reported a lower net loss allocable to common stockholders ... per share, compared to a net loss allocable to common stockholders ... per share, and a net loss allocable to common stockholders in ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9
... offers a range of standard, enhanced ... delivers therapy to meet the needs ... in commercial and clinical effectiveness and ... the SleepStyle 200 series is the ...
... The ResMed S6 Lightweight II CPAP ... microprocessor-controlled motor that maintains consistent pressure. ... and adjusting the settings easy, and ... and make adjustments is simple. This ...
The S8 Escape is the economy model of ResMeds S8 series. The S8 Escape is ideal for patients who want the convenience and portability of the S8 models but do not require the added comfort features of...
The S7 Elite is the premium device in ResMeds award-winning S7 series. All S7 devices include an option of integrated humidification....
Medicine Products: